


# NOVANTRONE<sup>®</sup> mitoxANTRONE for injection concentrate



#### WARNING

NOVANTRONE<sup>®</sup> (mitoxantrone for injection concentrate) should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents.

NOVANTRONE<sup>®</sup> should be given slowly into a freely flowing intravenous infusion. It must **never** be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. (See **ADVERSE REACTIONS, General**, Cutaneous and **DOSAGE AND ADMINISTRATION, Preparation and Administration Precautions**).

NOT FOR INTRATHECAL USE. Severe injury with permanent sequelae can result from intrathecal administration. (See **WARNINGS, General**)

Except for the treatment of acute nonlymphocytic leukemia, NOVANTRONE<sup>®</sup> therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm<sup>3</sup>. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving NOVANTRONE<sup>®</sup>.

**Cardiotoxicity:** Congestive heart failure (CHF), potentially fatal, may occur either during therapy with NOVANTRONE<sup>®</sup> or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative NOVANTRONE<sup>®</sup> dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In cancer patients, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m<sup>2</sup>. To mitigate the cardiotoxicity risk with NOVANTRONE<sup>®</sup>, prescribers should consider the following:

**All patients:** All patients should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to start of NOVANTRONE<sup>®</sup> therapy. All patients should have baseline quantitative evaluation of left ventricular ejection fraction (LVEF) using appropriate methodology (ex. Echocardiogram, multi-gated radionuclide angiography (MUGA), MRI, etc.).


**Multiple Sclerosis Patients:** MS patients with a baseline LVEF below the lower limit of normal should not be treated with NOVANTRONE<sup>®</sup>. MS patients should be assessed for cardiac signs and symptoms by history, physical examination and ECG prior to each dose. MS patients should undergo quantitative reevaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF. Additional doses of NOVANTRONE<sup>®</sup> should not be administered to multiple sclerosis patients who have experienced either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during NOVANTRONE<sup>®</sup> therapy. MS patients should not receive a cumulative NOVANTRONE<sup>®</sup> dose greater than 140 mg/m<sup>2</sup>. MS patients should undergo yearly quantitative LVEF evaluation after stopping NOVANTRONE<sup>®</sup> to monitor for late occurring cardiotoxicity. For additional information, see **WARNINGS, Cardiac Effects**, and **DOSAGE AND ADMINISTRATION**.

Secondary acute myelogenous leukemia (AML) has been reported in multiple sclerosis and cancer patients treated with mitoxantrone. In a cohort of mitoxantrone treated MS patients followed for varying periods of time, an elevated leukemia risk of 0.25% (2/802) has been observed. In a prospective, open-label tolerability and safety monitoring study of NOVANTRONE<sup>®</sup> treated MS patients followed for varying periods of time, three cases of leukemia were observed with an approximate elevated leukemia risk of 0.6% (3/509). Incidence rates may vary based on patient populations and concomitant or prior medications used. Postmarketing cases of secondary acute leukemia have also been reported during and following treatment with mitoxantrone. A complete blood count is recommended prior to each dose and each year after NOVANTRONE<sup>®</sup> therapy of multiple sclerosis to monitor for hematologic adverse events, including potential risk of secondary leukemia. In 1774 patients with breast cancer who received NOVANTRONE<sup>®</sup> concomitantly with other cytotoxic agents and radiotherapy, the cumulative risk of developing treatment-related AML, was estimated as 1.1% and 1.6% at 5 and 10 years, respectively (see **WARNINGS** section). Secondary acute myelogenous leukemia (AML) has been reported in cancer patients treated with anthracyclines. NOVANTRONE<sup>®</sup> is an anthracenedione, a related drug.

The occurrence of refractory secondary leukemia is more common when anthracyclines are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated.

#### DESCRIPTION

NOVANTRONE<sup>®</sup> (mitoxantrone hydrochloride) is a synthetic antineoplastic anthracenedione for intravenous use. The molecular formula is C<sub>23</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub>•2HC1 and the molecular weight is 517.41. It is supplied as a concentrate that MUST BE DILUTED PRIOR TO INJECTION. The concentrate is a sterile, nonpyrogenic, dark blue aqueous solution containing mitoxantrone hydrochloride equivalent to 2 mg/mL mitoxantrone free base, with sodium chloride (0.80% w/v), sodium acetate (0.005% w/v), and acetic acid (0.046% w/v) as inactive ingredients. The solution has a pH of 3.0 to 4.5 and contains 0.14 mg/L of sodium per mL. The product does not contain preservatives. The chemical name is 1,4-dihydroxy-



5,8-bis[2-[(2-hydroxyethyl) amino]ethyl]amino]-9,10- anthracenedione dihydrochloride and the structural formula is:

#### CLINICAL PHARMACOLOGY

**Mechanism of Action:** Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytoidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

NOVANTRONE<sup>®</sup> has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNF $\alpha$ , and IL-2.

--	--

**Pharmacokinetics:** Pharmacokinetics of mitoxantrone in patients following a single intravenous administration of NOVANTRONE<sup>®</sup> can be characterized by a three-compartment model. The mean alpha half-life of mitoxantrone is 6 to 12 minutes, the mean beta half-life is 1.1 to 3.1 hours and the mean gamma (terminal or elimination) half-life is 23 to 215 hours (median approximately 75 hours). Pharmacokinetic studies have not been performed in humans receiving multiple daily dosing. Distribution to tissues is extensive: steady-state volume of distribution exceeds 1,000 L/m<sup>2</sup>. Tissue concentrations of mitoxantrone appear to exceed those in the blood during the terminal elimination phase. In the healthy monkey, distribution to brain, spinal cord, eye, and spinal fluid is low.

In patients administered 15-90 mg/m<sup>2</sup> of NOVANTRONE<sup>®</sup> intravenously, there is a linear relationship between dose and the area under the concentration-time curve (AUC).

Mitoxantrone is 78% bound to plasma proteins in the observed concentration range of 26-455 ng/mL. This binding is independent of concentration and is not affected by the presence of phenytoin, doxorubicin, methotrexate, prednisone, prednisolone, heparin, or aspirin.

**Metabolism and Elimination:** Mitoxantrone is excreted in urine and feces as either unchanged drug or as inactive metabolites. In human studies, 11% and 25% of the dose were recovered in urine and feces, respectively, as either parent drug or metabolite during the 5-day period following drug administration. Of the material recovered in urine, 65% was unchanged drug. The remaining 35% was composed of monocarboxylic and dicarboxylic acid derivatives and their glucuronide conjugates. The pathways leading to the metabolism of NOVANTRONE<sup>®</sup> have not been elucidated.

#### Special Populations:

**Gender** - The effect of gender on mitoxantrone pharmacokinetics is unknown.

**Geriatric** - In elderly patients with breast cancer, the systemic mitoxantrone clearance was 21.3 L/hr/m<sup>2</sup>, compared with 28.3 L/hr/m<sup>2</sup> and 16.2 L/hr/m<sup>2</sup> for non-elderly patients with nasopharyngeal carcinoma and malignant lymphoma, respectively.

**Pediatric** - Mitoxantrone pharmacokinetics in the pediatric population are unknown.

**Race** - The effect of race on mitoxantrone pharmacokinetics is unknown.

**Renal Impairment** - Mitoxantrone pharmacokinetics in patients with renal impairment are unknown.

**Hepatic Impairment** - Mitoxantrone clearance is reduced by hepatic impairment. Patients with severe hepatic dysfunction (bilirubin > 3.4 mg/dL) have an AUC more than three times greater than that of patients with normal hepatic function receiving the same dose. Patients with multiple sclerosis who have hepatic impairment should ordinarily not be treated with NOVANTRONE<sup>®</sup>. Other patients with hepatic impairment should be treated with caution and dosage adjustment may be required.

**Drug Interactions:** In vitro drug interaction studies have demonstrated that mitoxantrone did not inhibit CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 across a broad concentration range. The results of in vitro induction studies are inconclusive, but suggest that mitoxantrone may be a weak inducer of CYP450 2E1 activity.

Pharmacokinetic studies of the interaction of NOVANTRONE<sup>®</sup> with concomitantly administered medications in humans have not been performed. The pathways leading to the metabolism of NOVANTRONE<sup>®</sup> have not been elucidated. To date, post-marketing experience has not revealed any significant drug interactions in patients who have received NOVANTRONE<sup>®</sup> for treatment of cancer. Information on drug interactions in patients with multiple sclerosis is limited.

#### CLINICAL TRIALS

**Multiple Sclerosis:** The safety and efficacy of NOVANTRONE<sup>®</sup> in multiple sclerosis were assessed in two randomized, multicenter clinical studies.

One randomized, controlled study (Study 1) was conducted in patients with secondary progressive or progressive relapsing multiple sclerosis. Patients in this study demonstrated significant neurological disability based on the Kurtzke Expanded Disability Status Scale (EDSS). The EDSS is an ordinal scale with 0.5 point increments ranging from 0.0 to 10.0 (increasing score indicates worsening) and based largely on ambulatory impairment in its middle range (EDSS 4.5 to 7.5 points). Patients in this study had experienced a mean deterioration in EDSS of about 1.6 points over the 18 months prior to enrollment.

Patients were randomized to receive placebo, 5 mg/m<sup>2</sup> NOVANTRONE<sup>®</sup>, or 12 mg/m<sup>2</sup> NOVANTRONE<sup>®</sup> administered IV every 3 months for 2 years. High-dose methylprednisolone was administered to treat relapses. The intent-to-treat analysis cohort consisted of 188 patients; 149 completed the 2-year study. Patients were evaluated every 3 months, and clinical outcome was determined after 24 months. In addition, a subset of patients was assessed with magnetic resonance imaging (MRI) at baseline, Month 12, and Month 24. Neurologic assessments and MRI reviews were performed by evaluators blinded to study drug and clinical outcome, although the diagnosis of relapse and the decision to treat relapses with steroids were made by unblinded treating physicians. A multivariate analysis of five clinical variables (EDSS, Ambulation Index [AI], number of relapses requiring treatment with steroids, months to first relapse needing treatment with steroids, and Standard Neurological Status [SNS]) was used to determine primary efficacy. The AI is an ordinal scale ranging from 0 to 9 in one point increments to define progressive ambulatory impairment. The SNS provides an overall measure of neurologic impairment and disability, with scores ranging from 0 (normal neurologic examination) to 99 (most possible score).

Results of Study 1 are summarized in Table 1.

Primary Endpoints	Treatment Groups			p-value
	Placebo (N = 64)	NOVANTRONE <sup>®</sup> 5 mg/m <sup>2</sup> (N = 64)	NOVANTRONE <sup>®</sup> 12 mg/m <sup>2</sup> (N = 60)	Placebo vs 12 mg/m <sup>2</sup> NOVANTRONE <sup>®</sup>
Primary efficacy multivariate analysis*	-	-	-	< 0.0001
<b>Primary clinical variables analyzed:</b>				
EDSS change** (mean)	0.23	-0.23	-0.13	0.0194
Ambulation Index change** (mean)	0.77	0.41	0.30	0.0306
Mean number of relapses per patient requiring corticosteroid treatment (adjusted for discontinuation)	1.20	0.73	0.40	0.0002
Months to first relapse requiring corticosteroid treatment (median [1st quartile])	14.2 [6.7]	NR [6.9]	NR [20.4]	0.0004
Standard Neurological Status change** (mean)	0.77	-0.38	-1.07	0.0269
<b>MRI#</b>				
No. of patients with new Gd-enhancing lesions	5/32 (16%)	4/37 (11%)	0/31	0.022
Change in number of T2-weighted lesions, mean (n)**	1.94 (32)	0.68 (34)	0.29 (28)	0.027

NR = not reached within 24 months; MRI = magnetic resonance imaging.

\* Wei-Lachin test.

\*\* Month 24 value minus baseline.

‡ A subset of 110 patients was selected for MRI analysis.

MRI results were not available for all patients at all time points.

A second randomized, controlled study (Study 2) evaluated NOVANTRONE<sup>®</sup> in combination with methylprednisolone (MP) and was conducted in patients with secondary progressive or worsening relapsing-remitting multiple sclerosis who had residual neurological deficit between relapses. All patients had experienced at least two relapses with sequelae or neurological deterioration within the previous 12 months. The average deterioration in EDSS was 2.2 points during the previous 12 months. During the screening period, patients were treated with two monthly doses of 1 g of IV MP and underwent monthly MRI scans. Only patients who developed at least one new Gd-enhancing MRI lesion during the 2-month screening period were eligible for randomization. A total of 42 evaluable patients received monthly treatments of 1 g of IV MP alone (n = 21) or ~12 mg/m<sup>2</sup> of IV NOVANTRONE<sup>®</sup> plus 1 g of IV MP (n = 21) (NOV + MP) for 6 months. Patients were evaluated monthly, and study outcome was determined after 6 months. The primary measure of effectiveness in this study was a comparison of the proportion of patients in each treatment group who developed no new Gd-enhancing MRI lesions at 6 months; these MRIs were assessed by a blinded panel. Additional outcomes were measured, including EDSS and number of relapses, but all clinical measures in this trial were assessed by an unblinded treating physician. Five patients, all in the MP alone arm, failed to complete the study due to lack of efficacy.

The results of this trial are displayed in Table 2.

Primary Endpoint	MP alone (N = 21)	NOV + MP (N = 21)	p-value
Patients (%) without new Gd-enhancing lesions on MRIs (primary endpoint)*	5 (31%)	19 (90%)	0.001
<b>Secondary Endpoints</b>			
EDSS change (Month 6 minus baseline)* (mean)	-0.1	-1.1	0.013
Annualized relapse rate (mean per patient)	3.0	0.7	0.003
Patients (%) without relapses	7 (33%)	14 (67%)	0.031

MP = methylprednisolone; NOV + MP = NOVANTRONE<sup>®</sup> plus methylprednisolone.

\* Results at Month 6, not including data for 5 withdrawals in the MP alone group.

**Advanced Hormone-Refractory Prostate Cancer:** A multicenter Phase 2 trial of NOVANTRONE<sup>®</sup> and low-dose prednisone (N + P) was conducted in 27 symptomatic patients with hormone-refractory prostate cancer. Using NPCP (National Prostate Cancer Project) criteria for disease response, there was one partial responder and 12 patients with stable disease. However, nine patients or 33% achieved a palliative response defined on the basis of reduction in analgesic use or pain intensity.

These findings led to the initiation of a randomized multicenter trial (CCI-NOV22) comparing the effectiveness of (N + P) to low-dose prednisone alone (P). Eligible patients were required to have metastatic or locally advanced disease that had progressed on standard hormonal therapy, a castrate serum testosterone level, and at least mild pain at study entry. NOVANTRONE<sup>®</sup> was administered at a dose of 12 mg/m<sup>2</sup> by short IV infusion every 3 weeks. Prednisone was administered orally at a dose of 5 mg twice a day. Patients randomized to the prednisone arm were crossed over to the N + P arm if they progressed or if they were not improved after a minimum of 6 weeks of therapy with prednisone alone.

A total of 161 patients were randomized, 80 to the N + P arm and 81 to the P arm. The median NOVANTRONE<sup>®</sup> dose administered was 12 mg/m<sup>2</sup> per cycle. The median cumulative NOVANTRONE<sup>®</sup> dose administered was 73 mg/m<sup>2</sup> (range of 12 to 212 mg/m<sup>2</sup>).

A primary palliative response (defined as a 2-point decrease in pain intensity in a 6-point pain scale, associated with stable analgesic use, and lasting a minimum of 6 weeks) was achieved in 29% of patients randomized to N + P compared to 12% of patients randomized to P alone (p = 0.011). Two responders led the study after meeting primary response criterion for two consecutive cycles. For the purposes of this analysis, these two patients were assigned a response duration of zero days. A secondary palliative response was defined as a 50% or greater decrease in analgesic use, associated with stable pain intensity, and lasting a minimum of 6 weeks. An overall palliative response

(defined as primary plus secondary responses) was achieved in 38% of patients randomized to N + P compared to 21% of patients randomized to P (p = 0.025).

The median duration of primary palliative response for patients randomized to N + P was 7.6 months compared to 2.1 months for patients randomized to P alone (p = 0.0009). The median duration of overall palliative response for patients randomized to N + P was 5.6 months compared to 1.9 months for patients randomized to P alone (p = 0.0004).

Time to progression was defined as a 1-point increase in pain intensity, or a > 25% increase in analgesic use, or evidence of disease progression on radiographic studies, or requirement for radiotherapy. The median time to progression for all patients randomized to N + P was 4.4 months compared to 2.3 months for all patients randomized to P alone (p = 0.0001). Median time to death was 11.3 months for all patients on the N + P arm compared to 10.8 months for all patients on P alone (p = 0.2324).

Forty-eight patients on the P arm crossed over to receive N + P. Of these, thirty patients had progressed on P, while 18 had stable disease on P. The median cycle of crossover was 5 cycles (range of 2 to 16 cycles). Time trends for pain intensity prior to crossover were significantly worse for patients who crossed over than for those who remained on P alone (p = 0.012). Nine patients (19%) demonstrated a palliative response on N + P after crossover. The median time to death for patients who crossed over to N + P was 12.7 months.

The clinical significance of a fall in prostate-specific antigen (PSA) concentrations after chemotherapy is unclear. On the CCI-NOV22 trial, a PSA fall of 50% or greater for two consecutive follow-up assessments after baseline was reported in 33% of all patients randomized to the N + P arm and 9% of all patients randomized to the P arm. These findings should be interpreted with caution since PSA responses were not defined prospectively. A number of patients were unevaluable for response, and there was an imbalance between treatment arms in the numbers of evaluable patients. In addition, PSA reduction did not correlate precisely with palliative response, the primary efficacy endpoint of this study. For example, among the 26 evaluable patients randomized to the N + P arm who had  $\geq$  50% reduction in PSA, only 13 had a primary palliative response. Also, among 42 evaluable patients on this arm who did not have this reduction in PSA, 8 nonetheless had a primary palliative response.

Investigators at Cancer and Leukemia Group B (CALGB) conducted a Phase 3 comparative trial of NOVANTRONE<sup>®</sup> plus hydrocortisone (N + H) versus hydrocortisone alone (H) in patients with hormone-refractory prostate cancer (CALGB 9182). Eligible patients were required to have metastatic disease that had progressed despite at least one hormonal therapy. Progression at study entry was defined on the basis of progressive symptoms, increases in measurable or osseous disease, or rising PSA levels. NOVANTRONE<sup>®</sup> was administered intravenously at a dose of 14 mg/m<sup>2</sup> every 21 days and hydrocortisone was administered orally at a daily dose of 40 mg. A total of 242 subjects were randomized, 119 to the N + H arm and 123 to the H arm. There were no differences in survival between the two arms, with a median of 11.1 months in the N + H arm and 12 months in the H arm (p = 0.3298).

Using NPCP criteria for response, partial responses were achieved in 10 patients (8.4%) randomized to the N + H arm compared with 2 patients (1.6%) randomized to the H arm (p = 0.018). The median time to progression, defined by NPCP criteria, for patients randomized to the N + H arm was 7.3 months compared to 4.1 months for patients randomized to H alone (p = 0.0654).

Approximately 60% of patients on each arm required analgesics at baseline. Analgesic use was measured in this study using a 5-point scale. The best percent change from baseline in mean analgesic use was -17% for 61 patients with available data on the N + H arm, compared with +17% for 61 patients on H alone (p = 0.014). A time trend analysis for analgesic use in individual patients also showed a trend favoring the N + H arm over H alone but was not statistically significant.

Pain intensity was measured using the Symptom Distress Scale (SDS) Pain Item 2 (a 5-point scale). The best percent change from baseline in mean pain intensity was -14% for 37 patients with available data on the N + H arm, compared with +8% for 38 patients on H alone (p = 0.057). A time trend analysis for pain intensity in individual patients showed no difference between treatment arms.

**Acute Nonlymphocytic Leukemia:** In two large randomized multicenter trials, remission induction therapy for acute nonlymphocytic leukemia (ANLL) with NOVANTRONE<sup>®</sup> 12 mg/m<sup>2</sup> daily for 3 days as a 10-minute intravenous infusion (cytarabine 100 mg/m<sup>2</sup> for 3 days given as a continuous 24-hour infusion was compared with daunorubicin 45 mg/m<sup>2</sup> daily by intravenous infusion for 3 days plus the same dose and schedule of cytarabine used with NOVANTRONE<sup>®</sup>. Patients who had an incomplete anti-leukemic response received a second induction course in which NOVANTRONE<sup>®</sup> or daunorubicin was administered for 2 days and cytarabine for 5 days using the same daily dosage schedule. Response rates and median survival information for both the U.S. and international multicenter trials are given in Table 3:

Trial	% Complete Response (CR)		Median Time to CR (days)		Survival (days)	
	NOV	DAUN	NOV	DAUN	NOV	DAUN
U.S.	63 (62/98)	53 (54/102)	35	42	312	237
International	50 (56/112)	51 (62/123)	36	42	192	230
NOV = NOVANTRONE <sup>®</sup> + cytarabine						
DAUN = daunorubicin + cytarabine						

In these studies, two consolidation courses were administered to complete responders on each arm. Consolidation therapy consisted of the same drug and daily dosage used for remission induction, but only 5 days of cytarabine and 2 days of NOVANTRONE<sup>®</sup> or daunorubicin were given. The first consolidation course was administered 6 weeks after the start of the final induction course if the patient achieved a complete remission. The second consolidation course was generally administered 4 weeks later. Full hematologic recovery was necessary for patients to receive consolidation therapy. For the U.S. trial, median granulocyte nadirs for patients receiving NOVANTRONE<sup>®</sup> + cytarabine for consolidation courses 1 and 2 were 10/mm<sup>3</sup> for both courses, and for those patients receiving daunorubicin + cytarabine nadirs were 170/mm<sup>3</sup> and 260/mm<sup>3</sup>, respectively. Median platelet nadirs for patients who received NOVANTRONE<sup>®</sup> + cytarabine for consolidation courses 1 and 2 were 17,000/mm<sup>3</sup> and 14,000/mm<sup>3</sup>, respectively, and were 33,000/mm<sup>3</sup> and 22,000/mm<sup>3</sup> in courses 1 and 2 for those patients who received daunorubicin + cytarabine. The benefit of consolidation therapy in ANLL patients who achieve a complete remission remains controversial. However, in the only well-controlled prospective, randomized multicenter trials with NOVANTRONE<sup>®</sup> in ANLL, consolidation therapy was given to all patients who achieved a complete remission. During consolidation in the U.S. study, two myelosuppression-related deaths occurred on the NOVANTRONE<sup>®</sup> arm and one on the daunorubicin arm. However, in the international study there were eight deaths on the NOVANTRONE<sup>®</sup> arm during consolidation which were related to the myelosuppression and none on the daunorubicin arm where less myelosuppression occurred.

#### INDICATIONS AND USAGE

NOVANTRONE<sup>®</sup> is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). NOVANTRONE<sup>®</sup> is not indicated in the treatment of patients with primary progressive multiple sclerosis.

The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.

NOVANTRONE<sup>®</sup> in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.

NOVANTRONE<sup>®</sup> in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

#### CONTRAINDICATIONS

NOVANTRONE<sup>®</sup> is contraindicated in patients who have demonstrated prior hypersensitivity to it.

#### WARNINGS

WHEN NOVANTRONE<sup>®</sup> IS USED IN HIGH DOSES (> 14 mg/m<sup>2</sup>/d x 3 days) SUCH AS INDICATED FOR THE TREATMENT OF LEUKEMIA, SEVERE MYELOSUPPRESSION WILL OCCUR. THEREFORE, IT IS RECOMMENDED THAT NOVANTRONE<sup>®</sup> BE ADMINISTERED ONLY BY PHYSICIANS EXPERIENCED IN THE CHEMOTHERAPY OF THIS DISEASE. LABORATORY AND SUPPORTIVE SERVICES MUST BE AVAILABLE FOR HEMATOLOGIC AND CHEMISTRY MONITORING AND ADJUNCTIVE THERAPIES, INCLUDING ANTIBIOTICS. BLOOD AND BLOOD PRODUCTS MUST BE AVAILABLE TO SUPPORT PATIENTS DURING THE EXPECTED PERIOD OF MEDULLARY HYPOPLASIA AND SEVERE MYELOSUPPRESSION. PARTICULAR CARE SHOULD BE GIVEN TO ASSURING FULL HEMATOLOGIC RECOVERY BEFORE UNDERTAKING CONSOLIDATION THERAPY (IF THIS TREATMENT IS USED) AND PATIENTS SHOULD BE MONITORED CLOSELY DURING THIS PHASE. NOVANTRONE<sup>®</sup> ADMINISTERED AT ANY DOSE CAN CAUSE MYELOSUPPRESSION.

**General:** Patients with preexisting myelosuppression as the result of prior drug therapy should not receive NOVANTRONE<sup>®</sup> unless it is felt that the possible benefit from such treatment warrants the risk of further medullary suppression.

The safety of NOVANTRONE<sup>®</sup> (mitoxantrone for injection concentrate) in patients with hepatic insufficiency is not established (see **CLINICAL PHARMACOLOGY**).

Safety for use by routes other than intravenous administration has not been established.

NOVANTRONE<sup>®</sup> is not indicated for subcutaneous, intramuscular, or intra-arterial injection. There have been reports of local/regional neuropathy, some irreversible, following intra-arterial injection.

NOVANTRONE<sup>®</sup> must not be given by intrathecal injection. There have been reports of neuropathy and neurotoxicity, both central and peripheral, following intrathecal injection. These reports have included seizures leading to coma and severe neurologic sequelae, and paralysis with bowel and bladder dysfunction.

Topoisomerase II inhibitors, including NOVANTRONE<sup>®</sup>, have been associated with the development of secondary AML and myelosuppression.

**Cardiac Effects:** Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of NOVANTRONE<sup>®</sup> therapy in such patients should be determined before starting therapy.

Functional cardiac changes including decreases in left ventricular ejection fraction (LVEF) and irreversible congestive heart failure can occur with NOVANTRONE<sup>®</sup>. Cardiac toxicity may be more common in patients with prior treatment with anthracyclines, prior mediastinal radiotherapy, or with preexisting cardiovascular disease. Such patients should have regular cardiac monitoring of LVEF from the initiation of therapy. Cancer patients who received cumulative doses of 140 mg/m<sup>2</sup> either alone or in combination with other chemotherapeutic agents had a cumulative 2.6% probability of clinical congestive heart failure. In comparative oncology trials, the overall cumulative probability rate of moderate or severe decreases in LVEF at this dose was 13%.

#### Multiple Sclerosis

Changes in cardiac function may occur in patients with multiple sclerosis treated with NOVANTRONE<sup>®</sup>. In one controlled trial (Study 1, see **CLINICAL TRIALS, Multiple Sclerosis**), two patients (2% of 127 receiving NOVANTRONE<sup>®</sup>, one receiving a 5 mg/m<sup>2</sup> dose and the other receiving the 12 mg/m<sup>2</sup> dose, had LVEF values that decreased to below 50%. An additional patient (dosed 12 mg/m<sup>2</sup>, who did not have LVEF measured, had a decrease in another echocardiographic measurement of ventricular function (fractional shortening) that led to discontinuation from the trial (see **ADVERSE REACTIONS, Multiple Sclerosis**). There were no reports of congestive heart failure in either controlled trial.

MS patients should be assessed for cardiac signs and symptoms by history, physical examination, ECG, and quantitative LVEF evaluation using appropriate methodology (ex. Echocardiogram, MUGA, MRI, etc.) prior to the start of NOVANTRONE<sup>®</sup> therapy. MS patients with a baseline LVEF below the lower limit of normal should not be treated with NOVANTRONE<sup>®</sup>. Subsequent LVEF and ECG evaluations are recommended if signs or symptoms of congestive heart failure develop and prior to every dose administered to MS patients. NOVANTRONE<sup>®</sup> should not be administered to MS patients who experience a reduction in LVEF to below the lower limit of normal, to those who experience a clinically significant reduction in LVEF, or to those who have received a cumulative lifetime dose of 140 mg/m<sup>2</sup>. MS patients should have yearly quantitative LVEF evaluation after stopping NOVANTRONE<sup>®</sup> to monitor for late-occurring cardiotoxicity.

**Leukemia:** Acute congestive heart failure may occasionally occur in patients treated with NOVANTRONE<sup>®</sup> for ANLL. In first-line comparative trials of NOVANTRONE

**Pregnancy:** Pregnancy Category D (see **WARNINGS**).

**Nursing Mothers:** NOVANTRONE is excreted in human milk and significant concentrations (18 ng/mL) have been reported for 28 days after the last administration. Because of the potential for serious adverse reactions in infants from NOVANTRONE, breast feeding should be discontinued before starting treatment.

**Pediatric Use:** Safety and effectiveness in pediatric patients have not been established.

**Geriatric Use:** Multiple Sclerosis: Clinical studies of NOVANTRONE® did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

*Hormone-Refractory Prostate Cancer:* One hundred forty-six patients aged 65 and over and 52 younger patients (<65 years) have been treated with NOVANTRONE® in controlled clinical studies. These studies did not include sufficient numbers of younger patients to determine whether they respond differently from older patients. However, greater sensitivity of some older individuals cannot be ruled out.

*Acute Nonlymphocytic Leukemia:* Although definitive studies with NOVANTRONE® have not been performed in geriatric patients with ANLL, toxicity may be more frequent in the elderly. Elderly patients are more likely to have age-related comorbidities due to disease or disease therapy.

**ADVERSE REACTIONS**

**Multiple Sclerosis:** NOVANTRONE® has been administered to 149 patients with multiple sclerosis in two randomized clinical trials, including 21 patients who received NOVANTRONE® in combination with corticosteroids.

In Study 1, the proportion of patients who discontinued treatment due to an adverse event was 9.7% (n = 6) in the 12 mg/m<sup>2</sup> NOVANTRONE® arm (leukopenia, depression, decreased LV function, bone pain and emesis, renal failure, and one discontinuation to prevent future complications from repeated urinary tract infections) compared to 3.1% (n = 2) in the placebo arm (hepatitis and myocardial infarction). The following clinical adverse experiences were significantly more frequent in the NOVANTRONE® groups: nausea, alopecia, urinary tract infection, and menstrual disorders, including amenorrhea.

Table 4a summarizes clinical adverse events of all intensities occurring in ≥ 5% of patients in either dose group of NOVANTRONE® and that were numerically greater on drug than on placebo in Study 1. The majority of these events were of mild to moderate intensity, and nausea was the only adverse event that occurred with severe intensity in more than one patient (three patients [5%] in the 12 mg/m<sup>2</sup> group). Of note, alopecia consisted of mild hair thinning.

Two of the 127 patients treated with NOVANTRONE® in Study 1 had decreased LVEF to below 50% at some point during the 2 years of treatment. An additional patient receiving 12 mg/m<sup>2</sup> did not have LVEF measured, but had another echocardiographic measure of ventricular function (fractional shortening) that led to discontinuation from the study.

Table 4a: Adverse Events of Any Intensity Occurring in ≥ 5% of Patients on Any Dose of NOVANTRONE® and That Were Numerically Greater Than in the Placebo Group Study 1

Preferred Term	Percent of Patients		
	Placebo (N = 64)	5 mg/m <sup>2</sup> NOVANTRONE® (N = 65)	12 mg/m <sup>2</sup> NOVANTRONE® (N = 62)
Nausea	20	55	76
Alopecia	31	38	61
Menstrual disorder *	26	51	61
Amenorrhea *	3	28	43
Upper respiratory tract infection	52	51	53
Urinary tract infection	13	29	32
Stomatitis	8	15	19
Arrhythmia	8	6	18
Diarrhea	11	25	16
Urine abnormal	6	5	11
ECG abnormal	3	5	11
Constipation	6	14	10
Back pain	5	6	8
Sinusitis	2	3	6
Headache	5	6	6

\* Percentage of female patients.

The proportion of patients experiencing any infection during Study 1 was 67% for the placebo group, 85% for the 5 mg/m<sup>2</sup> group, and 81% for the 12 mg/m<sup>2</sup> group. However, few of these infections required hospitalization: one placebo patient (tonsillitis), three 5 mg/m<sup>2</sup> patients (enteritis, urinary tract infection, viral infection), and four 12 mg/m<sup>2</sup> patients (tonsillitis, urinary tract infection [two], endometritis).

Table 4b summarizes laboratory abnormalities that occurred in ≥ 5% of patients in either NOVANTRONE® dose group, and that were numerically more frequent than in the placebo group.

Table 4b: Laboratory Abnormalities Occurring in ≥ 5% of Patients\* on Either Dose of NOVANTRONE® and That Were More Frequent Than in the Placebo Group Study 1

Event	Percent of Patients		
	Placebo (N = 64)	5 mg/m <sup>2</sup> NOVANTRONE® (N = 65)	12 mg/m <sup>2</sup> NOVANTRONE® (N = 62)
Leukopenia <sup>a</sup>	0	9	19
Gamma-GT increased	3	3	15
SGOT increased	8	9	8
Granulocytopenia <sup>b</sup>	2	6	6
Anemia	2	9	6
SGPT increased	3	6	5

\* Assessed using World Health Organization (WHO) toxicity criteria.

a. < 4000 cells/mm<sup>3</sup>

b. < 2000 cells/mm<sup>3</sup>

There was no difference among treatment groups in the incidence or severity of hemorrhagic events.

In Study 2, NOVANTRONE® was administered once a month. Clinical adverse events most frequently reported in the NOVANTRONE® group included amenorrhea (53% of female patients), alopecia (33% of patients), nausea (29% of patients), and asthenia (24% of patients). Tables 5a and 5b respectively summarize adverse events and laboratory abnormalities occurring in > 5% of patients in the NOVANTRONE® group and numerically more frequent than in the control group.

Table 5a: Adverse Events of Any Intensity Occurring in &gt; 5% of Patients\* in the NOVANTRONE® Group and Numerically More Frequent Than in the Control Group Study 2

	Percent of Patients	
	Event MP (n = 21)	N + MP (n = 21)
Amenorrhea <sup>a</sup>	0	53
Alopecia	0	33
Nausea	0	29
Asthenia	0	24
Pharyngitis/throat infection	5	19
Gastralgia/stomach burn/epigastric pain	5	14
Aphthosis	0	10
Cutaneous mycosis	0	10
Rhinitis	0	10
Menorrhagia <sup>a</sup>	0	7

N = NOVANTRONE®, MP = methylprednisolone

\* Assessed using National Cancer Institute (NCI) common toxicity criteria.

a. Percentage of female patients.

Table 5b: Laboratory Abnormalities Occurring in &gt; 5% of Patients\* in the NOVANTRONE® Group and Numerically More Frequent Than in the Control Group Study 2

	Percent of Patients	
	Event MP (n = 21)	N + MP (n = 21)
WBC low <sup>a</sup>	14	100
ANC low <sup>b</sup>	10	100
Lymphocytes low	43	95
Hemoglobin low	48	43
Platelets low <sup>c</sup>	0	33
SGOT high	5	15
SGPT high	10	15
Glucose high	5	10
Potassium low	0	10

N = NOVANTRONE®, MP = methylprednisolone.

\* Assessed using National Cancer Institute (NCI) common toxicity criteria.

a. < 4000 cells/mm<sup>3</sup>

b. < 1500 cells/mm<sup>3</sup>

c. < 100,000 cells/mm<sup>3</sup>

Leukopenia and neutropenia were reported in the N +MP group (see Table 5b). Neutropenia occurred within 3 weeks after NOVANTRONE® administration and was always reversible. Only mild to moderate intensity infections were reported in 9 of 21 patients in the N + MP group and in 3 of 21 patients in the MP group; none of these required hospitalization. There was no difference among treatment groups in the incidence or severity of hemorrhagic events. There were no withdrawals from Study 2 for safety reasons.

**Leukemia:** NOVANTRONE® has been studied in approximately 600 patients with acute non-lymphocytic leukemia (ANLL). Table 6 represents the adverse reaction experience in the large U.S. comparative study of mitoxantrone + cytarabine vs daunorubicin + cytarabine. Experience in the large international study was similar. A much wider experience in a variety of other tumor types revealed no additional important reactions other than cardiomyopathy (see **WARNINGS**). It should be appreciated that the listed adverse reaction categories include overlapping clinical symptoms related to the same condition, e.g. dyspnea, cough and pneumonia. In addition, the listed adverse reactions cannot all necessarily be attributed to chemotherapy as it is often impossible to distinguish effects of the drug and effects of the underlying disease. It is clear, however, that the combination of NOVANTRONE® + cytarabine was responsible for nausea and vomiting, alopecia, mucositis/stomatitis, and myelosuppression.

Table 6 summarizes adverse reactions occurring in patients treated with NOVANTRONE® + cytarabine in comparison with those who received daunorubicin + cytarabine for therapy of ANLL in a large multicenter randomized prospective U.S. trial.

Adverse reactions are presented as major categories and selected examples of clinically significant subcategories.

Event	Induction		Consolidation	
	NOV	DAUN	NOV	DAUN
	N = 102	N = 102	N = 55	N = 49
Cardiovascular	26	28	11	24
CHF	5	6	0	0
Arrhythmias	3	3	4	4
Bleeding	37	41	20	6
GI	16	12	2	2
Petechiae/ecchymoses	7	9	11	2
Gastrointestinal	88	85	58	51
Nausea/vomiting	72	67	31	31
Diarrhea	47	47	18	8
Abdominal pain	15	9	9	4
Mucositis/stomatitis	29	33	18	8
Hepatic	10	11	14	2
Jaundice	3	8	7	0
Infections	66	73	60	43
UTI	7	2	7	2
Pneumonia	9	7	9	0
Sepsis	34	36	31	18
Fungal infections	15	13	9	6
Renal failure	8	6	0	2
Fever	78	71	24	18
Alopecia	37	40	22	16
Pulmonary	43	43	24	14
Cough	13	9	9	2
Dyspnea	18	20	6	0
CNS	30	30	34	35
Seizures	4	4	2	8
Headache	10	9	13	8
Eye	7	6	2	4
Conjunctivitis	5	1	0	0

NOV = NOVANTRONE®, DAUN = daunorubicin.

**Hormone-Refractory Prostate Cancer:** Detailed safety information is available for a total of 353 patients with hormone-refractory prostate cancer treated with NOVANTRONE®, including 274 patients who received NOVANTRONE® in combination with corticosteroids.

Table 7 summarizes adverse reactions of all grades occurring in ≥ 5% of patients in Trial CCI-NOV22.

Event	N + P (N = 80)	P (N = 81)
Nausea	61	35
Fatigue	39	14
Alopecia	29	0
Anorexia	25	6
Constipation	16	14
Dyspnea	11	5
Nail bed changes	11	0
Edema	10	4
Systemic infection	10	7
Mucositis	10	0
UTI	9	4
Emesis	9	5
Pain	8	9
Fever	6	3
Hemorrhage/bruise	6	1
Anemia	5	3
Cough	5	0
Decreased LVEF	5	0
Anxiety/depression	5	3
Dyspepsia	5	6
Skin infection	5	3
Blurred vision	3	5

N = NOVANTRONE®, P = prednisone.

No nonhematologic adverse events of Grade 3/4 were seen in > 5% of patients.

Table 8 summarizes adverse events of all grades occurring in ≥ 5% of patients in Trial CALGB 9182.

Event	N + H (N = 112)	%	H (N = 113)	%
Decreased WBC	96	87	4	4
Granulocytes/bands	88	79	3	3
Decreased hemoglobin	83	75	42	39
Lymphocytes	78	72	27	25
Pain	45	41	44	39
Platelets	43	39	8	7
Alkaline Phosphatase	41	37	42	38
Malaise/fatigue	37	34	16	14
Hyperglycemia	33	31	32	30
Edema	31	30	15	14
Nausea	28	26	9	8
Anorexia	24	22	16	14
BUN	24	22	22	20
Transaminase	22	20	16	14
Alopecia	20	20	1	1
Cardiac function	19	18	0	0
Infection	18	17	4	4
Weight loss	18	17	13	12
Dyspnea	16	15	9	8
Diarrhea	16	14	4	4
Fever in absence of infection	15	14	7	6
Weight gain	15	14	16	15
Creatinine	14	13	11	10
Other gastrointestinal	13	14	11	11
Vomiting	12	11	6	5
Other neurologic	11	11	5	5
Hypocalcemia	10	10	5	5
Hematuria	9	11	5	6
Hyponatremia	9	9	3	3
Sweats	9	9	2	2
Other liver	8	8	8	8
Stomatitis	8	8	1	1
Cardiac dysrhythmia	7	7	3	3
Hypokalemia	7	7	4	4
Neuro/constipation	7	7	2	2
Neuro/motor	7	7	3	3
Neuro/mood	6	6	2	2
Skin	6	6	4	4
Cardiac ischemia	5	5	1	1
Chills	5	5	0	0
Hemorrhage	5	5	3	3
Myalgias/arthralgias	5	5	3	3
Other kidney/bladder	5	5	3	3
Other endocrine	5	6	3	4
Other pulmonary	5	5	3	3
Hypertension	4	4	5	5
Impotence/libido	4	7	2	3
Proteinuria	4	6	2	3
Sterility	3	5	2	3

N= NOVANTRONE®, H= hydrocortisone

**General:**

*Allergic Reaction* - Hypotension, urticaria, dyspnea, and rashes have been reported occasionally. Anaphylaxis/anaphylactoid reactions have been reported rarely.

*Cutaneous* - Extravasation at the infusion site has been reported, which may result in erythema, swelling, pain, burning, and/or blue discoloration of the skin. Extravasation can result in tissue necrosis with resultant need for debridement and skin grafting. Phlebitis has also been reported at the site of the infusion.

*Hematologic* - Topoisomerase II inhibitors, including NOVANTRONE®, in combination with other antineoplastic agents or alone, have been associated with the development of acute leukemia (see **WARNINGS**).

*Leukemia* - Myelosuppression is rapid in onset and is consistent with the requirement to produce significant marrow hypoplasia in order to achieve a response in acute leukemia. The incidences of infection and bleeding seen in the U.S. trial are consistent with those reported for other standard induction regimens.

*Hormone-Refractory Prostate Cancer* - In a randomized study where dose escalation was required for neutrophil counts greater than 1000/mm<sup>3</sup>, Grade 4 neutropenia (ANC < 500 /mm<sup>3</sup>) was observed in 54% of patients treated with NOVANTRONE® + low-dose prednisone. In a separate randomized trial where patients were treated with 14 mg/m<sup>2</sup>, Grade 4 neutropenia in 23% of patients treated with NOVANTRONE® + hydrocortisone was observed. Neutropenic fever/infection occurred in 11% and 10% of patients receiving NOVANTRONE® + corticosteroids, respectively, on the two trials. Platelets < 50,000/mm<sup>3</sup> were noted in 4% and 3% of patients receiving NOVANTRONE® + corticosteroids on these trials, and there was one patient death on NOVANTRONE® + hydrocortisone due to intracranial hemorrhage after a fall.

*Gastrointestinal* - Nausea and vomiting occurred acutely in most patients and may have contributed to reports of dehydration, but were generally mild to moderate and could be controlled through the use of antiemetics. Stomatitis/mucositis occurred within 1 week of therapy.

*Cardiovascular* - Congestive heart failure, tachycardia, EKG changes including arrhythmias, chest pain, and asymptomatic decreases in left ventricular ejection fraction have occurred (see **WARNINGS**).

*Pulmonary* - Interstitial pneumonitis has been reported in cancer patients receiving combination chemotherapy that included NOVANTRONE®.

**OVERDOSAGE**

There is no known specific antidote for NOVANTRONE®. Accidental overdoses have been reported. Four patients receiving 140-180 mg/m<sup>2</sup> as a single bolus injection died as a result of severe leukopenia with infection. Hematologic support and antimicrobial therapy may be required during prolonged periods of severe myelosuppression.

Although patients with severe renal failure have not been studied, NOVANTRONE® is extensively tissue bound and it is unlikely that the therapeutic effect or toxicity would be mitigated by peritoneal or hemodialysis.

**DOSAGE AND ADMINISTRATION** (see also **WARNINGS**)

**Multiple Sclerosis:** The recommended dosage of NOVANTRONE® is 12 mg/m<sup>2</sup> given as a short (approximately 5 to 15 minutes) intravenous infusion every 3 months. Left ventricular ejection fraction (LVEF) should be evaluated by echocardiogram or MUGA prior to administration of the initial dose of NOVANTRONE® and all subsequent doses. In addition, LVEF evaluations are recommended if signs or symptoms of congestive heart failure develop at any time during treatment with NOVANTRONE®. NOVANTRONE® should not be administered to multiple sclerosis patients with an LVEF <50%, with a clinically significant reduction in LVEF, or to those who have received a cumulative lifetime dose of ≥ 140 mg/m<sup>2</sup>. Complete blood counts, including platelets, should be monitored prior to each course of NOVANTRONE® and in the event that signs or symptoms of infection develop. NOVANTRONE® generally should not be administered to multiple sclerosis patients with neutrophil counts less than 1500 cells/mm<sup>3</sup>. Liver function tests should also be monitored prior to each course. NOVANTRONE® therapy in multiple sclerosis patients with abnormal liver function tests is not recommended because NOVANTRONE® clearance is reduced by hepatic impairment and no laboratory measurement can predict drug clearance and dose adjustments. Women with multiple sclerosis who are biologically capable of becoming pregnant, even if they are using birth control, should have a pregnancy test, and the results should be known, before receiving each dose of NOVANTRONE® (see **WARNINGS, Pregnancy**).

**Hormone-Refractory Prostate Cancer:** Based on data from two Phase 3 comparative trials of NOVANTRONE® plus corticosteroids versus corticosteroids alone, the recommended dosage of NOVANTRONE® is 12 to 14 mg/m<sup>2</sup> given as a short intravenous infusion every 21 days.

**Combination Initial Therapy for ANLL in Adults:** For induction, the recommended dosage is 12 mg/m<sup>2</sup> of NOVANTRONE® daily on Days 1-3 given as an intravenous infusion, and 100 mg/m<sup>2</sup> of cytarabine for 7 days given as a continuous 24-hour infusion on Days 1-7.

Most complete remissions will occur following the initial course of induction therapy. In the event of an incomplete anti-leukemic response, a second induction course may be given. NOVANTRONE® should be given for 2 days and cytarabine for 5 days using the same daily dosage levels.

If severe or life-threatening nonhematologic toxicity is observed during the first induction course, the second induction course should be withheld until toxicity resolves.

Consolidation therapy which was used in two large randomized multicenter trials consisted of NOVANTRONE®, 12 mg/m<sup>2</sup> given by intravenous infusion daily on Days 1 and 2 and cytarabine, 100 mg/m<sup>2</sup> for 5 days given as a continuous 24-hour infusion on Days 1 - 5. The first course was given approximately 6 weeks after the final induction course, the second was generally administered 4 weeks after the first. Severe myelosuppression occurred. (See **CLINICAL PHARMACOLOGY**)

**Hepatic Impairment:** For patients with hepatic impairment, there is at present no laboratory measurement that allows for dose adjustment recommendations. (See **CLINICAL PHARMACOLOGY, Special Populations, Hepatic Impairment**)

**Preparation and Administration Precautions**